FDA approves Onivyde as first-line treatment for metastatic pancreatic cancer

The FDA approved irinotecan liposome as part of a first-line regimen for the treatment of metastatic pancreatic adenocarcinoma.
Irinotecan liposome (Onivyde, Ipsen) is a topoisomerase inhibitor designed to be given as an IV injection and as part of a regimen — also known as NALIRIFOX — comprising the chemotherapy drugs oxaliplatin, fluorouracil, and leucovorin. The regimen previously received orphan drug designation from the FDA.
The regulator approved the irinotecan liposome-led regimen based on results from the phase 3 NAPOLI-3 trial. The multicenter study evaluated the saftey and

The FDA approved irinotecan liposome as part of a first-line regimen for the treatment of metastatic pancreatic adenocarcinoma.
Irinotecan liposome (Onivyde, Ipsen) is a topoisomerase inhibitor designed to be given as an IV injection and as part of a regimen — also known as NALIRIFOX — comprising the chemotherapy drugs oxaliplatin, fluorouracil, and leucovorin. The regimen previously received orphan drug designation from the FDA.
The regulator approved the irinotecan liposome-led regimen based on results from the phase 3 NAPOLI-3 trial. The multicenter study evaluated the saftey and